Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORAVEXX (CBD) for pain reduction after shoulder arthroscopy
NCT04672252Phase 3Completed
- Sponsor
- NYU Langone Health
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative pain comparing Cohort 1 - CBD with Cohort 2 - Placebo (2 cohorts). Primary endpoints: Pain Visual Analog Scale Score at Day 14 and Nausea Score on VAS Scale at Day 14. Started Dec 2020; status: completed.
02
Drugs
cannabidiol
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04672252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672252.